Mirna

Spacee's President Nominated Among 50 Innovators in AI

Retrieved on: 
Tuesday, February 21, 2023

DUBAI, UAE, Feb. 21, 2023 /PRNewswire/ -- Spacee, which provides the best computer vision and AI solutions for retailers and consumer brands, is proud to announce that its President, COO and Secretary of the Board, Mirna Abyad Baloul, has been nominated among 50 of the most innovative leaders in the Artificial Intelligence (AI) industry.

Key Points: 
  • DUBAI, UAE, Feb. 21, 2023 /PRNewswire/ -- Spacee, which provides the best computer vision and AI solutions for retailers and consumer brands, is proud to announce that its President, COO and Secretary of the Board, Mirna Abyad Baloul, has been nominated among 50 of the most innovative leaders in the Artificial Intelligence (AI) industry.
  • Mirna's nomination is a testament to her leadership and expertise in driving Spacee's mission of delivering solutions that make a meaningful impact on the retail industry.
  • Under her direction, Spacee has developed Hovertouch, a unique solution that brings products to life using computer vision and requires no screen or customer device.
  • "I am honoured to be recognised among 50 innovators in AI and to be part of a team that is shaping the future of the retail industry," said Mirna Abyad Baloul.

Spacee's President Nominated Among 50 Innovators in AI

Retrieved on: 
Tuesday, February 21, 2023

DUBAI, UAE, Feb. 21, 2023 /PRNewswire/ -- Spacee, which provides the best computer vision and AI solutions for retailers and consumer brands, is proud to announce that its President, COO and Secretary of the Board, Mirna Abyad Baloul, has been nominated among 50 of the most innovative leaders in the Artificial Intelligence (AI) industry.

Key Points: 
  • DUBAI, UAE, Feb. 21, 2023 /PRNewswire/ -- Spacee, which provides the best computer vision and AI solutions for retailers and consumer brands, is proud to announce that its President, COO and Secretary of the Board, Mirna Abyad Baloul, has been nominated among 50 of the most innovative leaders in the Artificial Intelligence (AI) industry.
  • Mirna's nomination is a testament to her leadership and expertise in driving Spacee's mission of delivering solutions that make a meaningful impact on the retail industry.
  • Under her direction, Spacee has developed Hovertouch, a unique solution that brings products to life using computer vision and requires no screen or customer device.
  • "I am honoured to be recognised among 50 innovators in AI and to be part of a team that is shaping the future of the retail industry," said Mirna Abyad Baloul.

uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1

Retrieved on: 
Tuesday, January 31, 2023

LEXINGTON, Mass. and AMSTERDAM and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, and Apic Bio, an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced that they have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a rare, genetic form of ALS. Under the agreement, uniQure acquires global rights for the development and commercialization of APB-102, adding to its pipeline of gene therapies to treat neurological disorders. The U.S. Food and Drug Administration has cleared the investigational new drug (IND) application for APB-102 and has granted Orphan Drug and Fast Track designations.

Key Points: 
  • Under the agreement, uniQure acquires global rights for the development and commercialization of APB-102, adding to its pipeline of gene therapies to treat neurological disorders.
  • The U.S. Food and Drug Administration has cleared the investigational new drug (IND) application for APB-102 and has granted Orphan Drug and Fast Track designations.
  • Mutations in the SOD1 gene of ALS account for approximately one-fifth of all inherited forms of this fatal disease1.
  • Relevant SOD1 reduction in spinal cord motor neurons also was demonstrated in rodents, as well as in non-human primates at proposed clinical doses.

Global miRNA Tools and Services Market Report 2022: Rising Use of Technological and Bioinformatics-Improved Systems Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022

The "Global miRNA Tools and Services Market Size, Share & Industry Trends Analysis Report by Technology (qRT-PCR, Extraction Tools, NGS, Microarray, Functional Analysis Tools), End-user, Product & Services, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global miRNA Tools and Services Market Size, Share & Industry Trends Analysis Report by Technology (qRT-PCR, Extraction Tools, NGS, Microarray, Functional Analysis Tools), End-user, Product & Services, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global miRNA Tools and Services Market size is expected to reach $939.8 million by 2028, rising at a market growth of 17.8% CAGR during the forecast period.
  • miRNA is a non-coding and small gene that is known to influence the expression of certain other genes.
  • Additionally, the application of miRNA is expected to rise due to the usage of technological and bioinformatics-improved systems (such as NGS).

miRNA Sequencing and Assay Market Report 2022: Rise in Adoption of RNA Sequencing Protocols in Biotechnology Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The global miRNA sequencing and assay market size is expected to reach USD 823.5 million by 2030.

Key Points: 
  • The global miRNA sequencing and assay market size is expected to reach USD 823.5 million by 2030.
  • The market is expected to register a CAGR of 13.25% from 2022 to 2030 owing to the growing application areas of miRNA sequencing in the healthcare sector.
  • Furthermore, these companies have entered into several strategic initiatives with research institutes to expand the sequencing application in research studies.
  • It has become a key research tool in biological research and several disease diagnoses
    By application, cancer dominated the market in 2021.

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Retrieved on: 
Monday, November 7, 2022

MILAN, Italy and NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA) (“Genenta” or the “Company”), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells (HSC) to provide durable and safe treatments for solid tumors, will present at the 2022 annual meeting of the Society for Immunotherapy of Cancer (SITC) data showing signs of Temferon-induced changes in the tumor microenvironment of patients affected by glioblastoma multiforme and activation of the immune system that may result in the inhibition of tumor growth.

Key Points: 
  • Single cell sequencing analyses of the TME unveiled a pro-inflammatory reprogramming of the myeloid and T cells compartment of Temferon-treated patients.
  • This pro-inflammatory pattern was associated in preclinical studies with tumor responses and in a fraction of mice with tumor eradication.
  • When you show that Temferon can re-tune the immune status of the tumor and its immediate surroundings under such challenging conditions, many treatment possibilities emerge.
  • Forward-looking statements contained in this announcement are made as of this date, and Genenta undertakes no duty to update such information except as required under applicable law.

Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting

Retrieved on: 
Thursday, October 20, 2022

The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119).

Key Points: 
  • The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119).
  • A secondary, retrospective analysis was also performed with ThyraMIRv2, the Companys new miRNA pairwise expression profiler.
  • Additionally, a blinded analysis of pairwise miRNA expression profiling demonstrated improved accuracy from the original testing platform.
  • Because of these and other risks, uncertainties, and assumptions, undue reliance should not be placed on these forward-looking statements.

Reproductive Technology Startup Inti Labs Sets Sights on Global Infertility Trend

Retrieved on: 
Thursday, October 20, 2022

PALO ALTO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Inti Labs, Inc. (Inti Labs) today announces its official launch and ambitious long-term vision to overcome infertility.

Key Points: 
  • PALO ALTO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Inti Labs, Inc. (Inti Labs) today announces its official launch and ambitious long-term vision to overcome infertility.
  • Those who choose to have children later often must rely on assisted reproductive technology (ART) such as IVF.
  • Among those joining Inti Labs' team is Dr. Barry Behr , fulfilling the role of Chief Technology Officer (CTO).
  • Inti Labs will be attending the 2022 ASRM Scientific Congress & Expo Oct 24-26 in Anaheim, CA, and invites you to visit their booth (#1433).

Pharus, Inc. Names Philip C. Huang as Company CEO, Becomes Newest Player in Cancer Liquid Biopsy Market

Retrieved on: 
Monday, October 3, 2022

LOS ANGELES, Oct. 3, 2022 /PRNewswire/ -- Pharus, Inc. ("PharusDx"), a new diagnostics company spun out from Hsinchu, Taiwan-based Quark Biosciences, has named Philip Huang as its Chief Executive Officer. PharusDx creates solutions for the early detection of cancer and is currently developing its OncoSweep™ Multi-Cancer Early Detection (MCED) liquid biopsy test as well as single-cancer liquid biopsy tests that evaluate microRNA (miRNA) within the body.

Key Points: 
  • PharusDx creates solutions for the early detection of cancer and is currently developing its OncoSweepMulti-Cancer Early Detection (MCED) liquid biopsy test as well as single-cancer liquid biopsy tests that evaluate microRNA (miRNA) within the body.
  • Before joining Roche, Mr. Huang was Vice President of Global Business Development for EKF Diagnostics, a UK point-of-care diagnostics company, where he led corporate strategy and solidified strategic partnerships.
  • PharusDx is entering the precision medicine market with the goal of changing cancer diagnosis, so that medical professionals can detect and treat cancer early, before it progresses to advanced disease.
  • Using OncoSweepMCED and single-cancer liquid biopsy tests, physicians can find circulating biomarkers for multiple forms of cancer by testing blood or other body fluid samples.

Exposing the evolutionary weak spots of the human genome

Retrieved on: 
Thursday, September 22, 2022

Cold Spring Harbor Laboratory (CSHL) Professor Adam Siepel 's team has created a computer program that tracks the history of harmful mutations in the human genome throughout evolution.

Key Points: 
  • Cold Spring Harbor Laboratory (CSHL) Professor Adam Siepel 's team has created a computer program that tracks the history of harmful mutations in the human genome throughout evolution.
  • They discovered parts of the genome are especially vulnerable to mutations, meaning any mutations in those regions can result in severe or lethal consequences.
  • By random chance, every part of the human genome should have mutations but some have none.
  • He also hopes his work will help further illustrate how mutations continue to shape the evolution of the human genome.